Farmas USA

Join Biotech Analysis Central and invest alongside Terry Chrisomalis

I chose to launch this service because there is a need for both traders and investors to understand the logic behind investing in a biotech stock. Most of these stocks trade accordingly by momentum. There can be gains made from knowing about other items in these biotech stocks. Such gains can be made from knowing about upcoming catalysts, potential trial results, and any other type of news event. I want to educate subscribers on what is the best approach when attempting to invest in this sector. Under my service, everyone will learn the ins/and outs of biotech investing. My goal is to prune everyone to better understand this sector and what is necessary to succeed in it.

Promotion Price (Exclusive Special)

We have reached past the 25 subscribers mark for the Biotech Analysis Central SA marketplace. As a Christmas special we are extending the lower legacy rate of $35 per month or $350 per year for the next 2 weeks only until Jan 1, 2018. At which time the rate shall increase to $49 per month or $490 per year. We encourage you to take advantage of this discount now before the rate increases starting the new year. As always there will be a 2-week free trial period to see if Biotech Analysis Central is right for you.

https://seekingalpha.com/checkout?slug=terry-chrisomalis

No, Framus, sigo dentro con órden de venta a 11.90, que quizás mañana suba a 12.40. No tengo prisa en venderlas, creo que 2018 será un buen año para éstas. Tú no volviste a comprar, no?

AMD

Puede ser que vuelvas a entrar por debajo de 3, de momento bajando en el after.

The net loss for the fiscal year ended October 31, 2017 was $93.4 million or $2.31 per share based on 40.5 million shares outstanding. This compares with a net loss for fiscal 2016 of $73.6 million or $2.08 per share based on 35.4 million shares outstanding.

Throughout fiscal 2018, Advaxis plans to continue to invest in its core clinical programs and expects its current cash position will be sufficient to fund its business plan into fiscal 2019.

“We’re fortunate that as immuno-oncology continues to evolve, the flexibility of our proprietary Lm Technology platform allows Advaxis to continue to adapt and introduce highly innovative programs.”

https://www.businesswire.com/news/home/20171220006059/en/Advaxis-Reports-Fiscal-Year-2017-Financial-Results

ADXS

No, no las compre. Pero estoy pensando en meterla un corto mañana, ya vere , segun la vaya viendo... AMD

TGTX cerro ayer superando su MM50, ya era hora!
A ver si confirma hoy ...

Ayer en el AH de ACHN, tochobloque de 1,8 mill de cromos a 2,84.

AMD

Debería cerrar ese gap del lunes antes de retomar la escalada , y mas tarde o mas temprano lo hará.

 PD.: Esta me gusta, le haré un marcaje férreo.

AMRN semanal

toma breakout de cuña!

SGYP Diario

TGTX

cierre por encima de su MM50 ... vamos a ver ese RSI si rompe de una vez...

ACAD

ese doji de ayer me tiene despistado ... pero MACD esta a punto de irse a bearish si no lo evitan hoy ...

En caso de suceder el movimiento bajista mientrada bien podria darse en el rango 26,5x-27,3x , ya veremos ...

ACHN MENSUAL

A ver si supera los 3$ de una vez y nos deja en mensual un martillo. Prepararia la vuelta para el 2018